SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshire Hathaway is trending as investors debate its massive cash pile and underperformance relative to the broader market, with many pinning their hopes on the upcoming annual meeting for clarity on CEO Greg Abels leadership strategy. Community sentiment is deeply divided between long-term supporters viewing the stock as a defensive value anchor and frustrated traders rotating into higher-growth AI and tech sectors.

Jupiter is a cryptocurrency exchange platform on the Solana blockchain, offering features such as token swapping, limit orders, dollar-cost averaging, and a bridge for asset transfers to Solana. It provides users with tools to find the best trading prices and includes a beta version for perpetual futures trading. Jupiter finds the best price route for your swap by aggregating all the major liquidity sources on Solana.

Jupiter

The community surrounding Jupiter's $UPDOG token is highlighting its long-term presence on the Solana network and its placement on the Jupiter Strict List. Active discussions are centered on persistent meme-based engagement, community building, and efforts to drive visibility through ongoing social outreach.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending after reports surfaced that the company is preparing an offer to acquire eBay, fueling aggressive retail speculation about a potential strategic pivot into e-commerce. While the community is actively debating the feasibility of the merger given the valuation gap, the news has ignited significant options activity and excitement over a potential short squeeze.

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

$SPERMWHALE is trending as investors actively discuss its potential for rapid price surges, utility features like buybacks, and its status within the volatile meme coin community. The conversation is driven by a mix of speculative enthusiasm for breaking new all-time highs and persistent debate regarding the project's sustainability compared to other emerging tokens.

Baby Doge Coin is a meme cryptocurrency designed to be deflationary and more scarce over time. All holders of Baby Doge will earn more baby doge that is automatically sent to your wallet by simply holding Baby Doge coins in your wallet. Watch the amount of baby doge grow in your wallet as baby doge coin holders automatically receive a 5% fee from every on chain transaction that happens on the Baby Doge ecosystem. The community receives more baby doge coins from the fees generated each transaction.

Baby Doge Coin

Baby Doge Coin is experiencing significant community momentum and trending interest as holders speculate on potential major exchange listings and a broader meme coin rally. Discussions are heavily focused on accumulating positions during price swings and the long-term potential for the token to reduce its circulating supply and erase zeros as market sentiment remains bullish.

eBay, Inc. is a commerce company, whose platforms include an online marketplace and its localized counterparts, including off-platform businesses in South Korea, Japan, and Turkey, as well as eBay’s suite of mobile apps. It offers a platform for various product categories, including parts and accessories, collectibles, fashion, electronics, and home & garden. eBay generates revenue mainly through fees from sales, payment processing, and advertising. The company was founded by Pierre Morad Omidyar in September 1995 and is headquartered in San Jose, CA.

EBay Inc.

eBay Inc

eBay is trending following a report that GameStop is building a stake in the company ahead of a potential acquisition offer, sparking widespread community debate over the feasibility of such a deal given the massive disparity in their market capitalizations. Investors are actively discussing the potential strategic fit for a retail-tech pivot versus concerns that the news is an elaborate market-driven distraction.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic remains a focal point for the community as investors debate the impact of potential burn mechanisms and the long-term viability of the chain's revival efforts. Discussions are heavily divided between those highlighting bullish technical patterns and opportunistic accumulation strategies, and others dismissing the asset as a speculative pump-and-dump venture.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin is capturing market attention as it gains traction on Base, fueled by the integration of AI-driven DeFi execution tools and expanded accessibility through recent exchange listings. The community remains highly active, debating the potential for long-term utility-driven growth while navigating the volatility inherent in speculative trading.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is currently a focal point for investors due to positive clinical data for its lead oral drug, Soquelitinib, which has fueled speculation regarding potential M&A activity and institutional accumulation. While the community is debating whether the stock is undergoing a healthy consolidation or a speculative pump, discussion remains heavily focused on upcoming clinical milestones and the potential for a major pharmaceutical acquisition.

The Mullen Army Token originated from a dedicated community of retail investors who faced challenges in the traditional stock market. We united to create a cryptocurrency that embodies our principles and aspirations for a fair financial system.     We provide a platform for retail investors to engage in a transparent and fair financial market. Our efforts include grassroots marketing, community engagement, and educational content to empower our investors.

MullenArmy

The MULN ticker remains a focal point for the "MullenArmy" community, which is debating whether the token is a speculative play for quick gains or a continuation of the negative sentiment surrounding the company's past history of dilution and reverse splits. While some traders are actively scouting for potential momentum and "weekend runner" opportunities, many community members are cautioning others against what they characterize as a high-risk, manipulative scam.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

LLY Stock Jumps After Q1 Earnings Beat, 2026 Guidance Raised

LLY jumps after crushing Q1 estimates and raising 2026 outlook, powered by surging Mounjaro and Zepbound sales and strong global demand.

Centessa Pharmaceuticals (NASDAQ:CNTA) Reaches New 12-Month High  - Still a Buy?

Centessa Pharmaceuticals (NASDAQ:CNTA) Sets New 52-Week High - Still a Buy...

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Short Interest Down 47.5% in April

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Get Free Report) was the recipient of a significant drop in short interest in the month of April. As of April 15th, there was short interest totaling 3,468,688 shares, a drop of 47.5% from the March 31st total of 6,607,633 shares. Based on...

<ul class="summary-bullets"><li>Eli Lilly notched up its sixth acquisition this year with the buyout of Ajax Therapeutics for $2.3 billion.</li><li>Other acquisitions this year include Orna and Kelonia for CAR-T cell therapy.</li><li>In March, Lilly agreed to spend $6.3 billion on Centessa Pharmaceuticals, a firm focused on treating sleep disorders like narcolepsy.</li></ul>Eli Lilly and Company (LLY) is accelerating its 2026 deal spree, notching its sixth acquisition with the buyout of Ajax Therapeutics as it pushes beyond weight-loss drugs to deepen its oncology pipeline.On Monday, Eli Lilly agreed to acquire Ajax Therapeutics in a deal valued at up to $2.3 billion, including milestone payments. The acquisition strengthens Lilly’s presence in blood cancer treatments.Ajax’s lead drug, AJ1-11095, is a next-generation JAK2 inhibitor currently in Phase 1 trials for patients with Myelofibrosis, a type of blood cancer.&nbsp; Lilly said the deal builds on its oncology expertise and aims to expand treatment options for patients with rare blood cancers such as Myelofibrosis and Polycythemia vera.<h2 class="st-heading-2">A Look At Lilly’s Acquisitions</h2>Lilly kicked off the year by agreeing to acquire Ventyx Biosciences, a San Diego-based clinical-stage company developing oral therapies for inflammatory-mediated diseases, in an all-cash deal worth approximately $1.2 billion, a 62% premium to Ventyx’s 30-day average trading price.Ventyx’s pipeline includes NLRP3 inhibitors targeting cardiometabolic, neurodegenerative, and inflammatory conditions.In February, Lilly announced plans to acquire Orna Therapeutics for up to $2.4 billion. Orna’s lead candidate, ORN-252, is a clinical trial-ready CAR-T therapy targeting CD19, a critical cell-surface protein used to treat autoimmune diseases. CAR-T therapies involve delivering genes or genetically engineered cells to help a patient’s immune system fight cancer.In March, Lilly agreed to spend $6.3 billion on Centessa Pharmaceuticals, betting on a portfolio of orexin receptor 2 (OX2R) agonists to treat sleep disorders like narcolepsy. Lilly also acquired CrossBridge Bio for $300 million to gain access to its next-generation cancer treatment, which uses a single antibody to deliver two different cell-killing drugs directly to tumor cells.Earlier this month, Lilly agreed to pay $3.25 billion upfront, and up to $7 billion in total, for Kelonia Therapeutics, which is developing an in vivo cell therapy in early clinical trials for multiple Myeloma. The Kelonia deal marks Lilly's second in vivo CAR-T acquisition of the year.<h2 class="st-heading-2">What Are Retail Traders Saying?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/LLY">LLY</a> on Stocktwits has remained in the ‘bullish’ territory over the past 24 hours, accompanied by ‘high’ message volumes.One user said that big pharma companies like Lilly typically make acquisitions when the risk-reward looks attractive for their pipeline.<stembedurl>https://stocktwits.com/3XL/message/651484609</stembedurl>Another user highlighted the importance of oncology in Lilly’s pipeline, given the massive market size.<stembedurl>https://stocktwits.com/LLYBULL/message/651487002</stembedurl>Overall, LLY shares have been under some selling pressure in 2026, declining nearly 20%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/asbp-stock-jumps-on-buyback-offer/cZBNwxzRePF">ASBP Stock Jumps 21% On Buyback Offer – Retail Believes Every Dip’s A Buying Opportunity</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A sign with the company logo sits outside of the headquarters campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, Indiana. (Photo by Scott Olson/Getty Images)

Eli Lilly’s Been On An Acquisition Spree This Year – Here’s A Look At Its Major Deals 

Eli Lilly made several multi-billion dollar acquisitions in 2026, with a strong focus on strengthening its oncology pipeline.

Equity

Should You Buy, Sell or Hold Lilly Stock Before Q1 Earnings?

Lilly heads into Q1 earnings with GLP-1 drugs driving growth. However, pricing pressure, rising costs, and softer Foundayo launch trends cloud the near-term outlook.

38,432 Shares in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Acquired by B. Metzler seel. Sohn & Co. AG

B. Metzler seel. Sohn & Co. AG purchased a new position in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 38,432 shares of the company's stock, valued at approximately $9...

LLY to Buy Oncology Biotech Kelonia Therapeutics for $7 Billion

Eli Lilly is set to acquire Kelonia Therapeutics in a $7B deal, boosting its genetic medicine platform with a novel in vivo CAR-T therapy for cancer.

Are CNTA, KORE, CWAN Obtaining Fair Deals for their Shareholders?

Are CNTA, KORE, CWAN Obtaining Fair Deals for their Shareholders? Are CNTA, KORE, CWAN Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, April 20, 2026 Insiders may stand to receive...

Centessa Pharmaceuticals' (CNTA) Equal Weight Rating Reaffirmed at Wells Fargo & Company

Wells Fargo & Company restated an "equal weight" rating and issued a $42.00 target price (up from $35.00) on shares of Centessa Pharmaceuticals in a research report on Monday...

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Given Consensus Rating of "Hold" by Analysts

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Get Free Report) has earned a consensus recommendation of "Hold" from the fourteen brokerages that are currently covering the firm...

Centessa Pharmaceuticals Plc operates as clinical-stage pharmaceutical company, which engages in discovering and developing medicines that delivers transformational to patients. Its portfolio include preclinical to phase three uncorrelated programs spanning diseases with high unmet need across oncology, hematology, immunology, inflammation, neuroscience, and rare diseases. The company was founded on October 26, 2020 and is headquartered in Altrincham, the United Kingdom.

CNTA
Centessa Pharmaceuticals PLC - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CNTA News

CNTACentessa Pharmaceuticals PLC - ADR